Isis and Excaliard Collaborate to Develop Antisense Drugs
Posted on: Tuesday, 27 November 2007, 12:01 CST
Isis Pharmaceuticals and Excaliard Pharmaceuticals have entered into a new collaboration to discover and develop antisense drugs for the local treatment of fibrotic diseases, including scarring.
Isis has granted Excaliard an exclusive worldwide license for the development and commercialization of certain antisense drugs. Excaliard made an upfront payment to Isis in the form of equity and paid Isis $1 million cash for the licensing of a particular gene target. In addition, Isis is eligible to receive development milestones and royalties on antisense drugs developed by Excaliard.
Lynne Parshall, executive vice president and CFO of Isis, said: "Excaliard will benefit from access to our technology and intellectual property and join a growing list of partners who have focused teams dedicated to advancing antisense drugs and who enable us to continue to expand the breadth of our antisense drug pipeline."
Source: Datamonitor
Related Articles
- Isis Initiates Phase 1 Clinical Trial of SGLT2 Antisense Drug
- AVI BioPharma's Antisense Drugs Found Effective Against Lethal Virus
- Isis Pharmaceuticals Cholesterol Drug Meets Trial Goals
- AVI BioPharma Announces Positive Clinical Trial Results Delivering NEUGENE Antisense Drugs to the Central Nervous System
- AVI Antisense Drug Battles Bird Flu
- Multiple Second-Generation Antisense Drugs Show Potential As New Treatments for Asthma
- Multiple Second-Generation Antisense Drugs Effectively Inhibit Tumor Growth and Show Potential As New Anti-Cancer Drugs
- AVI BioPharma Presents Positive Results With NEUGENE Antisense Drugs At the American Association for Cancer Research Meeting
- AVI BioPharma and USAMRIID Announce NEUGENE Antisense Drug Demonstrates Efficacy Against Ebola Virus
 |
 |
User Comments (0)
RSS Feeds